Merck strikes $3.5B collab with local RNA startup, invests in $221M Series B
Pharma giant Merck& Co. will partner with local startup Orna Therapeutics on multiple vaccines and treatments for infectious diseases and cancer. (Source: Health Care:Pharmaceuticals headlines)
Source: Health Care:Pharmaceuticals headlines - August 16, 2022 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Illumina Helped the World Fight COVID-19. Now, CEO Francis deSouza Has Monkeypox in His Sights
As chief executive of San Diego-based genomic sequencing company Illumina, Francis deSouza feels well-placed to witness the world’s next great scientific transformation. “I really believe that just like the 20th century was the era of the bit and the digital revolution, the 21st century is likely to be remembered as the era of the genome,” he says. “We’re seeing that play out in terms of genomic-based screening and diagnostics emerging, like Illumina’s offerings, but we’re also seeing the emergence of genomic-based medicine.” DeSouza’s excitement is understandable. Well...
Source: TIME: Health - August 14, 2022 Category: Consumer Health News Authors: John Simons Tags: Uncategorized biztech2030 The Leadership Brief Source Type: news

Mayo Clinic Minute: Don't skip your child's HPV vaccine
Kids are heading back into the classroom, and health care professionals say it's important to prepare for the first day of school by keeping up to date with childhood immunizations. Dr. Nipunie Rajapakse, a Mayo Clinic pediatric infectious diseases physician, says if you have a preteen, make sure he or she gets vaccinated for HPV now. It could prevent your child from getting cancer later in life.Watch: The Mayo Clinic Minute Journalists: Broadcast-quality video… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 11, 2022 Category: Databases & Libraries Source Type: news

FREE CONTACT HOUR: JHSON Virtual Nursing Grand Rounds
p{ margin:10px 0; padding:0; } table{ border-collapse:collapse; } h1,h2,h3,h4,h5,h6{ display:block; margin:0; padding:0; } img,a img{ border:0; height:auto; outline:none; text-decoration:none; } body,#bodyTable,#bodyCell{ height:100%; margin:0; padding:0; width:100%; } .mcnPreviewText{ display:none !important; } #outlook a{ padding:0; } img{ -ms-interpolation-mode:bicubic; } table{ mso-table-lspace:0pt; mso-table-rspace:0pt; } .ReadMsgBody{ width:100%; } .ExternalClass{ width:100%; } p,a,li,td,blockquote{ ...
Source: Johns Hopkins University and Health Systems Archive - August 10, 2022 Category: Nursing Source Type: news

When Treating Cervical Lesions, Adding HPV Vaccine Could Further Curb Cancer Risk
Title: When Treating Cervical Lesions, Adding HPV Vaccine Could Further Curb Cancer RiskCategory: Health NewsCreated: 8/5/2022 12:00:00 AMLast Editorial Review: 8/8/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 8, 2022 Category: Cancer & Oncology Source Type: news

54gene ’ s CEO Abasi Ene-Obong Wants to Fix the Racial Imbalance in Health Data
Born and raised in the Nigerian port city of Calabar, Abasi Ene-Obong remembers the exact moment that changed his life’s direction. Sitting in an introductory genetics class at medical school, in 2003, he heard the professor say that African genetic samples comprised less than 3% of health data bases in the world, creating a stunning vacuum in its ability to detect diseases and develop effective treatments for hundreds of millions of people. Ene-Obong ditched his plan to become a doctor, and instead left for London, and later Los Angeles, to study genetics, finally earning a Master’s degree in business focusing...
Source: TIME: Health - August 7, 2022 Category: Consumer Health News Authors: Vivienne Walt Tags: Uncategorized biztech2030 Innovation Leadership The Leadership Brief TIME 2030 Source Type: news

Cluster of Physician Deaths at Canadian Hospital Spurs Misinfo Campaign
(MedPage Today) -- When a Canadian health system lost three physicians to cancer within days of each other in mid-July, misinformation began swirling online that they had died as a result of receiving the COVID-19 vaccine. Alarming social media... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 5, 2022 Category: American Health Source Type: news

When Treating Cervical Lesions, Adding HPV Vaccine Could Further Curb Cancer Risk
FRIDAY, Aug. 5, 2022 -- Most sexually active people will contract the human papillomavirus (HPV) during their lifetimes, and about 90% will clear it from their bodies. But some women are susceptible to the cervical lesions that infection brings,... (Source: - Daily MedNews)
Source: - Daily MedNews - August 5, 2022 Category: General Medicine Source Type: news

1 in 4 Patients With NSCLC Respond Poorly to COVID-19 Vaccine 1 in 4 Patients With NSCLC Respond Poorly to COVID-19 Vaccine
About 1 in 4 patients with non –small cell lung cancer have an unsatisfactory antibody response to the Omicron variant following COVID-19 vaccination, reports a new study.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 5, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Kinnate Biopharma, led by a former vaccine CEO, hopes to reshape cancer drugs
"You've got to be agile in this business. You have to react," said Nima Farzan, who took over as CEO of Kinnate Biopharma as Covid shutdowns started. (Source: Health Care:Biotechnology headlines)
Source: Health Care:Biotechnology headlines - August 4, 2022 Category: Biotechnology Authors: Ron Leuty Source Type: news

European Commission Approves IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 4 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). The approval is based on the pivotal Phase 3 GLOW study that demonstrated superior progression-free survival (PFS) in patients treated with I+V versus chlorambucil-obinutuzumab (Clb+O), and the FD cohort of the Phase 2 CAPTIVATE study, which showed deep ...
Source: Johnson and Johnson - August 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Giving HPV jab to women with pre-cancerous cells on their cervix may ward off cancer, study suggests
Imperial College London researchers reviewed studies involving thousands of women vaccinated against HPV who had to have pre-cancerous cells removed. (Source: the Mail online | Health)
Source: the Mail online | Health - August 3, 2022 Category: Consumer Health News Source Type: news

HPV vaccine after removal of precancerous cells may cut cervical cancer risk
Study finds reduced risk of cervical cancer recurring after HPV vaccination post-surgery, though further research is neededGiving women the human papillomavirus (HPV) vaccine when precancerous lesions are removed from their cervix may cut the risk of cells recurring and them getting cervical cancer, a study has found.Cases of cervical cancerin the UK have fallen hugely since school pupils aged 13 and 14 – first girls and later boys – began being offered HPV jabs in 2008 as protection against the disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 3, 2022 Category: Science Authors: Denis Campbell Health policy editor Tags: Health Cervical cancer HPV vaccine Vaccines and immunisation Women Women's health UK news Cancer research Medical research Source Type: news

Recent cancer diagnosis or treatment lowers COVID-19 vaccine effectiveness, UK Covid Vaccine Research Hub
This new study, published in the European Journal of Cancer, set out to evaluate the effectiveness of the third vaccine dose in over 360,000 people with cancer, compared to the general population, using data from Public Health England ' s national cancer dataset between December 2020 to December 2021. Overall, the researchers found that third vaccines doses were less effective in people with cancer than in the general population and concluded that many people with cancer remain at increased risk of infection, even after three doses. Lower vaccine effectiveness was found to be associated with: a cancer diagnosis in the pr...
Source: Current Awareness Service for Health (CASH) - August 2, 2022 Category: Consumer Health News Source Type: news

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news